Published: 7 March 2024
Publications
Recent approvals: new active ingredients or new indications
Published 7 March 2024
Prescriber Update 45(1): 17–18
March 2024
New active ingredients
Table 1 shows recent approval of medicines with new active ingredients gazetted during the period 13 October 2023 to 1 February 2024.
Table 1: Recent approvals of medicines with new active ingredients
| Medicine | New active ingredienta | Dose form: strength(s) | Therapeutic area |
|---|---|---|---|
| Verzenio | Abemaciclib | Film coated tablet: 50mg, 100mg, 150mg | Breast cancer (hormone receptor [HR] positive, human epidermal growth factor receptor 2 [HER2] negative) |
| Ryeqo 40/1/0.5 | Relugolix | Film coated tablet: 40mg/1mg/0.5mg | Uterine fibroids |
| Tukysa | Tucatinib | Film coated tablet: 50mg, 150mg | Breast cancer (HER2 positive) |
| Comirnaty Omicron XBB 1.5 | Raxtozinameran | Suspension for injection: 0.1mg/mL | COVID-19 prevention |
| Tremfya | Guselkumab | Solution for injection (pen and syringe): 100mg/mL | Adults with plaque psoriasis or psoriatic psoriasis |
| Vumerity | Diroximel fumarate | Enteric coated capsule: 231mg | Relapsing multiple sclerosis |
- The medicine may also contain other active ingredients
New indications
Table 2 shows approved medicines with new indications for additional therapeutic areas gazetted during the period 13 October 2023 to 1 February 2024.
Table 2: Approved medicines with new indications for additional therapeutic areas
| Medicine (active ingredient) | Dose form: strength(s) | New therapeutic area |
|---|---|---|
| Jardiance (empagliflozin) | Film coated tablet: 10mg, 25mg | Chronic kidney disease |
More information
See the Medsafe website for:
